Skip to main content

Small for Gestational Age

4
Pipeline Programs
4
Companies
2
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
3
Early DiscoveryClinical DevelopmentMarket

On Market (2)

Approved therapies currently available

Pfizer
GENOTROPINApproved
somatropin
Pfizer
injection1995
27M Part D
Pfizer
GENOTROPIN PRESERVATIVE FREEApproved
somatropin
Pfizer
injection1995

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
1 program
1
SomatropinN/A1 trial
Active Trials
NCT00793325Completed920Est. Dec 2012
Sandoz
SandozAustria - Kundl
1 program
1
OmnitropePhase 4
Amoytop Biotech
Amoytop BiotechChina - Xiamen
1 program
1
somatropinPhase 3
Novartis
NovartisBASEL, Switzerland
1 program
OmnitropePHASE_41 trial
Active Trials
NCT00537914Completed278Est. Mar 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
NovartisOmnitrope
PfizerSomatropin

Clinical Trials (2)

Total enrollment: 1,198 patients across 2 trials

Safety and Efficacy of Omnitrope® (rhGH) in Short Children Born Small for Gestational Age (SGA)

Start: Feb 2008Est. completion: Mar 2022278 patients
Phase 4Completed

Long Term Use of Somatropin in Patients Small for Gestational Age

Start: Feb 2009Est. completion: Dec 2012920 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.